H.B. Fuller has cleared a critical hurdle in its proposed acquisition of Advanced Medical Solutions Group (AMS), after AMS shareholders approved the transaction at specially convened meetings on August 12, 2026. The approval moves the deal closer to completion, with closing expected by the end of the calendar year, subject to the remaining conditions and regulatory requirements.
The development is strategically significant for H.B. Fuller. The world’s largest pureplay adhesives company is using the acquisition to accelerate its move into higher-growth, higher-margin medical applications, while expanding its technology portfolio and global healthcare footprint.
A £715 Million Bet on Medical Adhesives
Under the recommended cash offer, eligible AMS shareholders will receive £2.85 per share, implying a total enterprise value of approximately £715 million. H.B. Fuller says the transaction will be fully financed through committed financing.
The deal gives H.B. Fuller access to AMS’s specialised medical technologies, including tissue-bonding adhesives, tapes and dressings, and formulated biosurgicals. These products serve healthcare applications where technical performance, regulatory expertise and product reliability can create higher barriers to entry than in many traditional adhesive markets.
For H.B. Fuller, the acquisition is therefore not simply about adding revenue. It is about changing the composition of the business.
Healthcare Becomes a Bigger Growth Engine
AMS is expected to increase H.B. Fuller’s total addressable market by approximately $15 billion, taking it to $95 billion, according to the company.
The acquisition is also expected to add approximately $300 million to H.B. Fuller’s annual revenue. H.B. Fuller expects the combination to create opportunities for cross-selling by connecting AMS’s pan-European healthcare sales network with H.B. Fuller’s established U.S. infrastructure.
AMS also brings more than 75 R&D professionals and manufacturing capabilities across the UK, Germany, France, the Netherlands, Thailand and India. Its regulatory expertise in medical devices could be particularly valuable as H.B. Fuller expands deeper into healthcare markets.
The Synergy Question
H.B. Fuller expects approximately $55 million in combined run-rate revenue and cost synergies by 2031. The company expects these benefits to come from sourcing savings, elimination of public-company costs and rationalisation of overlapping expenses.
But the projected synergies are not automatic. The real challenge begins after closing: integrating two businesses across geographies while protecting customer relationships, innovation pipelines and regulatory capabilities.
The transaction carries a pre-synergy EBITDA multiple of 12.9 times, based on the 2026 consensus forecast cited by H.B. Fuller. Including the full run-rate synergies, the company says the multiple would fall below eight times.
That makes execution central to the investment case.
Activist Investors Raise the Stakes
The AMS transaction is also taking place against increasing pressure from activist investors.
On August 12, Ancora Holdings proposed acquiring H.B. Fuller’s Building Adhesive Solutions business for $1.1 billion to $1.2 billion in cash. Ancora has argued that a divestiture could help H.B. Fuller focus on integrating AMS and concentrate on higher-value businesses. H.B. Fuller said its board would evaluate the proposal with financial and legal advisers.
The pressure intensified on August 14, when Engine Capital urged H.B. Fuller’s board to conduct a market check for the Building Adhesive Solutions segment and the entire company. Engine has questioned the valuation paid for AMS, the increased leverage and the execution risks associated with the transaction.
This puts greater scrutiny on H.B. Fuller’s capital-allocation strategy. Management is effectively arguing that AMS will help create a more attractive, healthcare-oriented portfolio, while activists are questioning whether shareholders would benefit more from a different portfolio structure.
More Than an Acquisition
The AMS deal represents a broader transformation in H.B. Fuller’s strategy.
The company has identified medical as a core growth market because of its expected demand profile, regulatory barriers and margin characteristics. AMS gives H.B. Fuller a deeper technology base and a stronger position in specialised healthcare applications.
But the acquisition also creates a clear test for management. H.B. Fuller must now prove that the premium paid for AMS can translate into stronger growth, improved margins and sustainable shareholder value.
The shareholder approval is therefore a milestone, not the conclusion.
The next chapter will be measured by integration, deleveraging and the delivery of the promised synergies. At the same time, the company will need to demonstrate that its healthcare-led portfolio strategy can create more value than the alternatives being proposed by activist investors.
For H.B. Fuller, the question is no longer whether AMS can be acquired. It is whether the acquisition can successfully reshape the company.
